絞り込み

16639

広告

Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.

著者 Zekri J , Farag K , Yousof O , Zabani Y , Mohamed W , Ahmed GA
J Oncol Pharm Pract.2019 Oct 01 ; ():1078155219877929.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (10view , 0users)

Full Text Sources

Bone metastases are common in patients with breast cancer and can lead to pain and skeletal-related events. Bone modifying agents are licensed to be used for these patients. We report the treatment patterns and outcome of zoledronic acid and denosumab in routine practice.
PMID: 31575357 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード